Photonic Hydrogel Beads for Controlled Release of Risedronate

被引:4
作者
Khajuria, Deepak Kumar [1 ]
Mahapatra, D. Roy [1 ]
机构
[1] Indian Inst Sci, Dept Aerosp Engn, Lab Integrat Multiscale Engn Mat & Syst, Bangalore 560012, Karnataka, India
来源
PHOTONIC THERAPEUTICS AND DIAGNOSTICS X | 2014年 / 8926卷
关键词
Hydrogel; Sodium alginate; Risedronate; Bisphosphonate; Drug release; Osteoporosis; Fluorescence; POSTMENOPAUSAL OSTEOPOROSIS; BISPHOSPHONATES; BONE; PHARMACOKINETICS; FRACTURES; DISEASE; TRIAL; WOMEN;
D O I
10.1117/12.2042568
中图分类号
O43 [光学];
学科分类号
070207 ; 0803 ;
摘要
pH-sensitive photonic composite hydrogel beads composed of sodium alginate and risedronate sodium (SA/RIS) was prepared crosslinked by Ca2+ owing to the ionic gelation of SA. The structure and surface morphology of the composite hydrogel beads were characterized by SEM. pH-sensitivity of these composite hydrogels beads and the release behaviors of drug from them were investigated. The results showed that the composite hydrogel beads had good pH-sensitivity. The drug loading and encapsulation efficiency were 27.7% and 92% for RIS, respectively. The cumulative release ratios of RIS from the composite hydrogel beads were 2.47% in pH 2.1 solution and 83 % in pH 6.8 solutions within 24 h, respectively. However, the cumulative release ratio of RIS in pH 7.4 solution reached 91% within 7 h. It is proposed that the novel photonic SA/RIS composite hydrogel bead could possess the potential of an increased intestinal absorption and fewer adverse effects of RIS. The pH and salt response of photonic hydrogel bead, as well as the encapsulation of macromolecules, are promising for applications in biomedicine and biotechnology.
引用
收藏
页数:7
相关论文
共 12 条
[1]   The management of Paget's disease of bone [J].
Delmas, PD ;
Meunier, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (08) :558-566
[2]   Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption [J].
Ezra, A ;
Golomb, G .
ADVANCED DRUG DELIVERY REVIEWS, 2000, 42 (03) :175-195
[3]   Bisphosphonates: Preclinical aspects and use in osteoporosis [J].
Fleisch, HA .
ANNALS OF MEDICINE, 1997, 29 (01) :55-62
[4]   Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis - A randomized controlled trial [J].
Harris, ST ;
Watts, NB ;
Genant, HK ;
McKeever, CD ;
Hangartner, T ;
Keller, M ;
Chesnut, CH ;
Brown, J ;
Eriksen, EF ;
Hoseyni, MS ;
Axelrod, DW ;
Miller, PD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (14) :1344-1352
[5]   Bisphosphonates and the treatment of bone disease in the elderly [J].
Johansen, A ;
Stone, M ;
Rawlinson, F .
DRUGS & AGING, 1996, 8 (02) :113-126
[6]   Bisphosphonates: A review of their pharmacokinetic properties [J].
Lin, JH .
BONE, 1996, 18 (02) :75-85
[7]   Effect of renal function on risedronate pharmacokinetics after a single oral dose [J].
Mitchell, DY ;
St Peter, JV ;
Eusebio, RA ;
Pallone, KA ;
Kelly, SC ;
Russell, DA ;
Nesbitt, JD ;
Thompson, GA ;
Powell, JH .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (03) :215-222
[8]   Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration [J].
Mitchell, DY ;
Barr, WH ;
Eusebio, RA ;
Stevens, KAP ;
Duke, FP ;
Russell, DA ;
Nesbitt, JD ;
Powell, JH ;
Thompson, GA .
PHARMACEUTICAL RESEARCH, 2001, 18 (02) :166-170
[9]   Bisphosphonate-associated adverse events [J].
Papapetrou, Peter D. .
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2009, 8 (02) :96-110
[10]   Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis [J].
Reginster, JY ;
Minne, HW ;
Sorensen, OH ;
Hooper, M ;
Roux, C ;
Brandi, ML ;
Lund, B ;
Ethgen, D ;
Pack, S ;
Roumagnac, I ;
Eastell, R .
OSTEOPOROSIS INTERNATIONAL, 2000, 11 (01) :83-91